AXSM - Axsome Therapeutics, Inc.
NEXT EARNINGS:
May 11, 2026
EPS Est: $-0.58
|
Rev Est: $193.3M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$222.43
DETAILS
HIGH:
$260.00
LOW:
$200.00
MEDIAN:
$221.00
CONSENSUS:
$222.43
UPSIDE:
30.88%
Market Cap:
8.57B
Volume:
1,060,989
Avg Volume:
629,358
52 Week Range:
86.99-191.5
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.40
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
712
IPO Date:
2015-11-19
EPS (TTM):
-3.68
P/E Ratio:
-49.60
Revenue (TTM):
638.50M
Total Assets:
689.80M
Total Debt:
215.57M
Cash & Equiv:
322.93M
Rev Growth (5Y):
177.6%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
2.44
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-23 | $-0.56 | $-0.70 | +19.4% | $196.0M | $192.4M | +1.9% |
| 2025-11-03 | $-0.94 | $-0.82 | -14.6% | $171.0M | $191.3M | -10.6% |
| 2025-08-04 | $-0.92 | $-1.00 | +8.0% | $150.0M | $140.0M | +7.2% |
| 2025-05-05 | $-0.80 | $-1.26 | +36.5% | $121.5M | $140.4M | -13.5% |
| 2025-02-18 | $-0.96 | $-1.00 | +4.0% | $118.8M | $119.5M | -0.6% |
| 2024-11-12 | $-1.34 | $-1.38 | +2.9% | $104.8M | $98.4M | +6.5% |
| 2024-08-05 | $-1.24 | $-1.30 | +4.6% | $87.2M | $86.9M | +0.3% |
| 2024-05-06 | $-1.09 | $-1.20 | +9.2% | $75.0M | $86.7M | -13.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 638.50M | 385.69M | 270.60M | 50.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (183.17M) | (287.22M) | (239.24M) | (187.13M) | (130.40M) | (102.90M) | (68.35M) | (30.97M) | (28.94M) | (27.20M) | (12.21M) | (6.00M) |
| EPS | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.83 | -2.05 | -1.15 | -1.27 | -1.42 | -0.88 | -0.47 |
| Total Assets | 689.80M | 568.50M | 588.24M | 331.48M | 87.79M | 186.13M | 220.55M | 15.38M | 35.56M | 38.21M | 49.08M | 2.79M |
| Total Debt | 215.57M | 192.96M | 186.37M | 94.68M | 49.71M | 50.12M | 19.93M | 6.91M | 9.93M | 9.74M | 0 | 4.48M |
| Cash & Equivalents | 322.93M | 315.35M | 386.19M | 200.84M | 86.47M | 183.88M | 219.97M | 13.97M | 34.02M | 36.62M | 48.04M | 2.62M |
| Operating Cash Flow | (93.41M) | (128.41M) | (145.08M) | (116.51M) | (108.23M) | (78.46M) | (46.38M) | (30.05M) | (26.47M) | (21.28M) | (7.44M) | (4.60M) |
| Free Cash Flow | (93.41M) | (128.68M) | (145.66M) | (117.21M) | (108.53M) | (78.50M) | (46.39M) | (30.09M) | (26.48M) | (21.39M) | (7.46M) | (4.60M) |
| FCF per Share | -1.88 | -2.69 | -3.21 | -2.88 | -2.89 | -2.11 | -1.36 | -1.12 | -1.16 | -1.12 | -0.62 | -0.36 |
| Book Value | 88.30M | 57.02M | 190.98M | 109.56M | 15.63M | 113.79M | 178.72M | 937,921 | 16.72M | 21.57M | 46.44M | (3.20M) |
| Cash & ST Investments | 322.93M | 315.35M | 386.19M | 200.84M | 86.47M | 183.88M | 219.97M | 13.97M | 34.02M | 36.62M | 48.04M | 2.62M |
| ROC Equity | -2.07 | -5.04 | -1.25 | -1.71 | -8.34 | -0.90 | -0.38 | -33.02 | -1.73 | -1.26 | -0.26 | N/A |